Faculty Disclosures
| Sasha Alick-Lindstrom, MD, MPH, FACNS, FAES, FAAN |
Dr. Alick-Lindstrom has nothing to disclose. |
| Meriem K. Bensalem Owen, MD |
Dr. Bensalem Owen has received personal compensation in the range of $0-$499 for serving as a Principle Investigator (PI) with Xenon. Dr. Bensalem Owen has received personal compensation in the range of $0-$499 for serving as a PI with UCB. Dr. Bensalem Owen has received personal compensation in the range of $0-$499 for serving as a PI with NeuroPace. |
| Lakshmi S. Amaravadi, PhD |
No disclosure on file
|
| Amit Ahituv |
Ms. Ahituv has nothing to disclose. |
| Maria Pleshkevich |
Maria Pleshkevich has nothing to disclose. |
| Claude Steriade, MD |
The institution of Dr. Steriade has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for The Epilepsy Study Consortium. Dr. Steriade has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Dynamed. Dr. Steriade has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for DOJ. The institution of Dr. Steriade has received research support from NIH. Dr. Steriade has received personal compensation in the range of $500-$4,999 for serving as a Consultant with Epitel. Dr. Steriade has received personal compensation in the range of $500-$4,999 for serving as a Consultant with Jazz Pharmaceuticals. Dr. Steriade has received personal compensation in the range of $10,000-$49,999 for serving as a Speakers Bureau with SK Life Sciences. Dr. Steriade has received personal compensation in the range of $5,000-$9,999 for serving as a Speakers Bureau with Neurelis. Dr. Steriade has received personal compensation in the range of $5,000-$9,999 for serving as a Advisory Board with Xenon Pharmaceuticals. |
| Anureet Kaur |
No disclosure on file
|
| Eden Tefera, BS |
Ms. Tefera has nothing to disclose. |
|
No disclosure on file
|
| Brad K. Kamitaki, MD |
Dr. Kamitaki has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brown and Brown Absence Services Group. The institution of Dr. Kamitaki has received research support from New Jersey Health Foundation. The institution of Dr. Kamitaki has received research support from National Institute on Aging. |
| Uma Sarwadnya |
Miss Sarwadnya has nothing to disclose. |
| Leila Alidoost |
No disclosure on file
|
| Jennifer Geller |
No disclosure on file
|
| Kylie Getz |
Kylie Getz has nothing to disclose. |
| Jennifer Dai, MD |
Ms. Dai has nothing to disclose. |
| Alejandra Duque Ramirez, MD |
Dr. Duque Ramirez has nothing to disclose. |
| Asra Tanwir, MD, MBBS |
Dr. Tanwir has nothing to disclose. |
| Charles A. Szabo, MD, FAAN |
Dr. Szabo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova. Dr. Szabo has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Epilepsy Foundation of Central and South Texas. Dr. Szabo has received personal compensation in the range of $0-$499 for serving as a Reviewer with NINDS. |
| Irwin Hollander, PhD |
No disclosure on file
|
| Soo Hyun Ahn, MD |
Dr. Ahn has nothing to disclose. |
| Yoonhyuk Jang, MD, PhD |
Mr. Jang has nothing to disclose. |
| Su Yee Mon |
Su Yee Mon has nothing to disclose. |
| Han Sang Lee |
No disclosure on file
|
| Kon Chu |
Kon Chu has nothing to disclose. |
| Sang Kun Lee, MD |
Prof. Lee has nothing to disclose. |
| Soon-Tae Lee, MD, PhD |
Prof. Lee has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Advanced Neural Technologies. Prof. Lee has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Piehealthcare. Prof. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Salted. Prof. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Prof. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Prof. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. The institution of Prof. Lee has received research support from Roche. Prof. Lee has received intellectual property interests from a discovery or technology relating to health care. |
| Kyung Il Park |
No disclosure on file
|
| Ji Hye You, NP |
Ms. YOU has nothing to disclose. |
| Jiping Zhou, MD, MPH |
Dr. Zhou has nothing to disclose. |
| Rohit A. Marawar, MD, FAAN |
Dr. Marawar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Marawar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Pharma. Dr. Marawar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurelis. The institution of Dr. Marawar has received research support from Catalyst Pharma. |
| Tabassum Chowdhury |
Ms. Chowdhury has nothing to disclose. |
| Melissa Ly |
Miss Ly has nothing to disclose. |
| Jason Liu |
Mr. Liu has nothing to disclose. |
| Shatha Wahbi |
Ms. Wahbi has nothing to disclose. |
| Manik Tetarbe, MD |
Dr. Tetarbe has nothing to disclose. |
| Maysaa M. Basha, MD, FAAN |
Dr. Basha has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. |
| Deepti Zutshi, MD, FAAN |
Dr. Zutshi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon pharmaceuticals. An immediate family member of Dr. Zutshi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. The institution of Dr. Zutshi has received research support from UCB Pharmaceuticals. |
| Gabriel Biondo |
Mr. Biondo has nothing to disclose. |
| Rachel Sukonnik |
No disclosure on file
|
| Caitlin Grzeskowiak |
No disclosure on file
|
| Gary R. Cutter, PhD |
Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN. |
| Jacqueline French, MD, FAAN |
Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Epilepsy Foundation. The institution of Dr. French has received research support from Epilepsy Study Consortium/ Epilepsy Foundation (Funded by UCB). The institution of Dr. French has received research support from GW/One8 Foundation/FACES. The institution of Dr. French has received research support from NINDS. The institution of Dr. French has received research support from Xenon. The institution of Dr. French has received research support from Cerevel. The institution of Dr. French has received research support from FACES. The institution of Dr. French has received research support from UCB. The institution of Dr. French has received research support from Epilepsy Study Consortium. The institution of Dr. French has received research support from UCB. The institution of Dr. French has received research support from Praxis. Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as a Chief Medical/Innovation Officer with Epilepsy Foundation. Dr. French has a non-compensated relationship as a Consultant with Acadia Pharmaceuticals Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Access Industries that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Acuta Capital Partners LLC that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with AFASCI Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Agrithera, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Alkermes that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Alterity Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Angelini Pharma S.p.A. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Autifony Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Axonis Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bain Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Beacon Biosciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Biogen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Biohaven Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Bloom Science, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bright Minds Biosciences, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Capsidia Biotherapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Cerebral Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cerecin, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Cerevel that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, SAB with Cognizance Biomarkers that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ceribell that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cowen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Crossject that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board with EcoR1 Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EG 427 that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant, Advisory Board with Eisai that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Encoded Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant/Advisory Board with Engrail that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Epitel, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EpiMinder that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Grin Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Harmony that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board with Ionis Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with iQure Pharma, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with IQVIA that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Janssen Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Jazz Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Leal Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, with Livanova that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with London Research & Pharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Longboard Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Maplight Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Marinus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Medscape/Web MD that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Modulight Bio that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Montara Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Mosaica Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neumarker that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Neumirna Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neurelis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board with Neurocrine that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neuropace that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with NeuroPro Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Neuroventis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Neurona Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board with Neuvarti that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Noema that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ono Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board with Otsuka that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board with Ovid Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Praxis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with PureTech LYT Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with QurAlis Corp that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Rapport Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Receptor Holdings, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Rivervest Venture Partners that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Sage Therapeutics, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with SK Life Science that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Stoke that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Stream Neuroscience that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Supernus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Takeda that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Taysha Gene Therapies that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with UCB, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with uniQure that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Ventus Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Vida Ventures Management that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Xenon Pharmaceuticals that is relevant to AAN interests or activities. |
| Ojas Potnis |
Mr. Potnis has nothing to disclose. |
| Joseph Medina |
No disclosure on file
|
| Eda Coban |
No disclosure on file
|
| Aria F. Terango |
No disclosure on file
|
| Lauren Waldron, MD |
Dr. Waldron has nothing to disclose. |
| Shaun Hussain, MD |
Dr. Hussain has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MGC Pharma. Dr. Hussain has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zogenix. Dr. Hussain has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Grenwich Biosciences. |
| David Tabibzadeh |
No disclosure on file
|
| Norah Gidanian |
No disclosure on file
|
| Rujuta Sathe |
No disclosure on file
|
| Emmi Deckard |
No disclosure on file
|
| Rajsekar R. Rajaraman, MD |
Dr. Rajaraman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Marinus Pharmacueticals. |
| Hiroki Nariai, MD |
Dr. Nariai has nothing to disclose. |
| Ritesh Ramdhani, MD |
Dr. Ramdhani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Encora Therapeutics. Dr. Ramdhani has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Encora Therapeutics. The institution of Dr. Ramdhani has received research support from NIH. Dr. Ramdhani has received research support from Parkinson Alliance. Dr. Ramdhani has received intellectual property interests from a discovery or technology relating to health care. |
| Julie Xian |
No disclosure on file
|
| Michael Kaufman |
No disclosure on file
|
| Sarah Ruggiero |
No disclosure on file
|
| Mark Ramos |
No disclosure on file
|
| Alexander Gonzalez |
No disclosure on file
|
| Amanda Back |
No disclosure on file
|
| Lea Bailey-Medley |
No disclosure on file
|
| Stacey Cohen |
No disclosure on file
|
| Vishnu A. Cuddapah, MD |
Dr. Cuddapah has received research support from NIH. Dr. Cuddapah has received research support from CURE Epilepsy. |
| Colin A. Ellis, MD |
Dr. Ellis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epiminder. |
| Natalie Ginn |
No disclosure on file
|
| Naomi Lewin, MD |
Dr. Lewin has nothing to disclose. |
| Laina Lusk |
Laina Lusk has received personal compensation in the range of $0-$499 for serving as a Consultant for Ambry Genetics. The institution of Laina Lusk has received research support from NINDS. |
| Eric D. Marsh, MD, PhD |
Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmacuticals. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia Pharmaceuticals. The institution of Dr. Marsh has received research support from NIH. The institution of Dr. Marsh has received research support from Rett Syndrome Research Trust. The institution of Dr. Marsh has received research support from International Rett Syndrome Foundation. The institution of Dr. Marsh has received research support from Eagles Autism Challenge. The institution of Dr. Marsh has received research support from LouLou Foundation. The institution of Dr. Marsh has received research support from International CDKL5 Resarch Foundation. The institution of Dr. Marsh has received research support from Acadia Pharmaceuticals. The institution of Dr. Marsh has received research support from Marinus. The institution of Dr. Marsh has received research support from Stoke Therapeutics. The institution of Dr. Marsh has received research support from Takeda Pharmaceuticals. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Grant Review with NIH. Dr. Marsh has received personal compensation in the range of $5,000-$9,999 for serving as a Expert Witness with Department of Human Services. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Medscape. |
| Shavonne Massey, MD |
Dr. Massey has a non-compensated relationship as a consultant with Sun Pharmaceutical Ltd that is relevant to AAN interests or activities. |
| Xilma R. Ortiz-Gonzalez, MD, PhD |
The institution of Dr. Ortiz-Gonzalez has received research support from Robert Wood Johnson Foundation . The institution of Dr. Ortiz-Gonzalez has received research support from NINDS. |
| Pamela Pojomovsky McDonnell, MD |
Dr. Pojomovsky McDonnell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Connected Research. Dr. Pojomovsky McDonnell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ceribell. |
| Katie Rose Sullivan |
No disclosure on file
|
| Katherine Taub |
No disclosure on file
|
| Sarah F. Tefft |
Ms. Tefft has nothing to disclose. |
| Katherine Helbig |
No disclosure on file
|
| Ethan M. Goldberg, MD, PhD |
Dr. Goldberg has nothing to disclose. |
| Ingo Helbig, MD |
Ingo Helbig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Encoded Therapeutics, Inc. Ingo Helbig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Capsida Biotherapeutics. The institution of Ingo Helbig has received research support from NIH. |
| Mark P. Fitzgerald, MD, PhD |
Dr. Fitzgerald has nothing to disclose. |
| Michelle Fabian, MD, FAAN |
Dr. Fabian has nothing to disclose. |
| Monika Thapa, MBBS |
Dr. Thapa has nothing to disclose. |
| Abdullahi Musa Adamu, MBBS |
Dr. Adamu has nothing to disclose. |
| Mostafa Hotait, MD |
Dr. Hotait has nothing to disclose. |
| Roohi Katyal, MD |
Dr. Katyal has nothing to disclose. |
| Vijayakumar Javalkar, MD, FAAN |
Dr. Javalkar has nothing to disclose. |
| Prabandh R. Buchhanolla, MBBS |
Dr. Buchhanolla has nothing to disclose. |
| Lakshmi Chandaluri |
No disclosure on file
|
| Saurabh Kataria, MD |
Dr. Kataria has nothing to disclose. |